Boston Scientific Enters into a Definitive Agreement to Acquire SoniVie for $600M
Shots:
- Boston Scientific entered into a definitive agreement to acquire SoniVie Ltd. to expand its interventional cardiology therapies offerings
- Currently, the company holds an equity stake of approx. 10%, and for the remaining 90% stake, the company will pay approx. $360M upfront and up to $180M regulatory milestones; for 100% stake, the amount sums up to $400M upfront and $200M regulatory milestone; transaction completion is expected in H1’25
- TIVUS Intravascular Ultrasound System is the lead asset of the company that is an investigational device developed to treat a variety of hypertensive disorders, incl. renal artery denervation, and currently the device is being investigated in THRIVE global IDE pivotal trial
Ref: Boston Scientific | Image: SoniVie
Related News:- The US FDA Grants Approval to Boston Scientific’s Farapulse Pulsed Field Ablation (PFA) System for Atrial Fibrillation (AF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com